Skip Navigation



Annals of Oncology Advance Access published online on July 10, 2006
Annals of Oncology, doi:10.1093/annonc/mdl155
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
18/2/215    most recent
mdl155v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Beslija, S.
Right arrow Articles by Zwierzina, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Beslija, S.
Right arrow Articles by Zwierzina, H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society for Medical Oncology
Received February 20, 2006
Revised May 26, 2006
Accepted May 26, 2006

review

Second consensus on medical treatment of metastatic breast cancer

S. Beslija 1, J. Bonneterre 1, H. Burstein 1, V. Cocquyt 1, M. Gnant 1, P. Goodwin 1, V. Heinemann 1, J. Jassem 1, W. J. Köstler 1, M. Krainer 1, S. Menard 1, T. Petit 1, L. Petruzelka 1, K. Possinger 1, P. Schmid 1, E. Stadtmauer 1, M. Stockler 1, S. Van Belle 1, C. Vogel 1, N. Wilcken 1, C. Wiltschke 1, C. C. Zielinski 1 *, and H. Zwierzina 1

1 Central European Cooperative Oncology Group (CECOG){sect}, Schwarzspanierstrasse 7/5, A-1090 Vienna, Austria

* To whom correspondence should be addressed.
C. C. Zielinski, E-mail: christoph.zielinski{at}meduniwien.ac.at


  Abstract

The present consensus manuscript defines evidence-based recommendations for state-of-the-art treatment of metastatic breast cancer depending on disease-associated and biologic variables.

Keywords: chemotherapy; endocrine therapy; medical treatment; metastatic breast cancer; targeted therapy.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
R. Largillier, J.-M. Ferrero, J. Doyen, J. Barriere, M. Namer, V. Mari, A. Courdi, J. M. Hannoun-Levi, F. Ettore, I. Birtwisle-Peyrottes, et al.
Prognostic factors in 1038 women with metastatic breast cancer
Ann. Onc., July 17, 2008; (2008) mdn424v1.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. Bartsch, C. Wenzel, G. Altorjai, U. Pluschnig, M. Rudas, R. M. Mader, M. Gnant, C. C. Zielinski, and G. G. Steger
Capecitabine and Trastuzumab in Heavily Pretreated Metastatic Breast Cancer
J. Clin. Oncol., September 1, 2007; 25(25): 3853 - 3858.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
S. Verma and M. Clemons
First-Line Treatment Options for Patients with HER-2 Negative Metastatic Breast Cancer: The Impact of Modern Adjuvant Chemotherapy
Oncologist, July 1, 2007; 12(7): 785 - 797.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.